NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT01568866,Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients,https://clinicaltrials.gov/study/NCT01568866,ENDEAVOR,COMPLETED,The primary objective of this study was to compare progression-free survival in patients with multiple myeloma who relapsed after 1 to 3 prior therapies treated with carfilzomib plus dexamethasone or bortezomib plus dexamethasone.,YES,Multiple Myeloma,DRUG: Carfilzomib|DRUG: Bortezomib|DRUG: Dexamethasone,"Progression-free Survival, Progression-free survival (PFS) was defined as the time from randomization to the earlier of disease progression or death due to any cause. Participants were evaluated for disease response and progression according to the International Myeloma Working Group-Uniform Response Criteria (IMWG-URC) as assessed by an Independent Review Committee (IRC).

Median PFS was estimated using the Kaplan-Meier method. Participants with no baseline disease assessments, starting a new anticancer therapy before documentation of disease progression or death, death or disease progression immediately after more than 1 consecutively missed disease assessment visit, or alive without documentation of disease progression before the data cut-off date were censored., From randomization until the data cut-off date of 10 November 2014; median follow-up time for PFS was 11.1.and 11.9 months in the bortezomib and carfilzomib arms respectively","Overall Survival, Overall survival (OS) is defined as the time from randomization to the date of death (whatever the cause). Participants who were alive or lost to follow-up as of the data analysis cut-off date were censored at the patient's date of last contact (last known to be alive).

Median overall survival was estimated using the Kaplan-Meier method., From randomization until the data cut-off date of 03 January 2017; median follow-up time for OS was 36.9 and 37.5 months for each treatment group respectively.|Overall Response, Disease response was evaluated according to the IMWG-URC by the IRC. Overall response was defined as the percentage of participants with a best overall response of partial response (PR), very good PR (VGPR), complete response (CR) or stringent CR (sCR).

sCR: As for CR, normal serum free light chain (SFLC) ratio and no clonal cells in bone marrow (BM).

CR: No immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas and \< 5% plasma cells in BM biopsy; VGPR: Serum and urine M-protein detectable by immunofixation but not electrophoresis or ≥ 90% reduction in serum M-protein with urine M-protein \<100 mg/24 hours. A ≥ 50% reduction in the size of soft tissue plasmacytomas if present at baseline.

PR: ≥ 50% reduction of serum M-protein and reduction in urine M-protein by ≥ 90% or to \< 200 mg/24 hours. A ≥ 50% reduction in the size of soft tissue plasmacytomas if present at baseline., Disease response was assessed every 28 days until end of treatment or the data cut-off date of 10 November 2014; median duration of treatment was 27 weeks in the bortezomib group and 40 weeks in the carfilzomib treatment group.|Duration of Response, Duration of response (DOR) was calculated for participants who achieved an sCR, CR, VGPR, or PR. Duration of response is defined as the time from first evidence of PR or better to confirmation of disease progression or death due to any cause. Median duration of response was estimated using the Kaplan-Meier method. Participants with no baseline disease assessments, starting a new anticancer therapy before documentation of disease progression or death, death or disease progression immediately after more than 1 consecutively missed disease assessment visit, or alive without documentation of disease progression before the data cut-off date were censored., From randomization until the data cut-off date of 10 November 2014; median follow-up time for DOR was 9.4 and 10.4 months for each treatment group respectively.|Percentage of Participants With ≥ Grade 2 Peripheral Neuropathy, Neuropathy events were defined as Grade 2 or higher peripheral neuropathy as specified by peripheral neuropathy Standardised Medical Dictionary for Regulatory Activities (MedDRA) Query, narrow (scope) (SMQN) terms.

Peripheral neuropathy was assessed by neurologic exam and graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03:

Grade 1: Asymptomatic; Grade 2: Moderate symptoms, limiting instrumental activities of daily living (ADL) Grade 3: Severe symptoms; limiting self-care ADL; Grade 4: Life-threatening consequences, urgent intervention indicated; Grade 5: Death., From the first dose of study drug up to 30 days after the last dose of study drug as of the data cut-off date of 10 November 2014; median duration of treatment was 27 weeks in the bortezomib group and 40 weeks in the carfilzomib treatment group.|Percentage of Participants With a Significant Reduction in Left Ventricular Ejection Fraction (LVEF), A significant reduction in LVEF was defined as a ≥ 10% decrease (absolute change) from baseline in participants whose baseline LVEF is ≤ 55%.

For participants with LVEF \> 55% at baseline, a significant change was defined as a decrease in LVEF to \< 45%., Baseline and 24 weeks|Change From Baseline in Right Ventricular Fractional Area Change (FAC), Right ventricular function was assessed by measuring fractional area change (FAC) on echocardiogram., Baseline and Weeks 12, 24 and 36 and at end of treatment (median duration of treatment was 27 weeks in the bortezomib group and 40 weeks in the carfilzomib treatment group).|Change From Baseline in Pulmonary Artery Systolic Pressure (PASP), Pulmonary artery pressure was measured using transthoracic echocardiogram., Baseline and Weeks 12, 24 and 36 and at end of treatment (median duration of treatment was 27 weeks in the bortezomib group and 40 weeks in the carfilzomib treatment group).",,Amgen,,ALL,"ADULT, OLDER_ADULT",PHASE3,929,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2011-003|2012-000128-16,2012-06-20,2014-11-10,2018-02-05,2012-04-02,2015-12-11,2022-11-14,"Providence St. Joseph Medical Center, Burbank, California, United States|UCSD Moore Cancer Center, La Jolla, California, United States|UCLA Medical Center, Los Angeles, California, United States|Central Coast Medical Oncology Group, Santa Maria, California, United States|Colorado Blood Cancer Institute, Denver, Colorado, United States|MAB Oncology/Hematology, Melbourne, Florida, United States|Palm Beach Cancer Institute, West Palm Beach, Florida, United States|Winship Cancer Institute, Atlanta, Georgia, United States|Hematology Oncology of Indiana, PC, Indianapolis, Indiana, United States|Center for Cancer and Blood Disorders, Bethesda, Maryland, United States|Associates in Oncology/Hematology PC, Rockville, Maryland, United States|University of Michigan, Ann Arbor, Michigan, United States|University of Kansas, Kansas City, Missouri, United States|Hackensack University Medical Ctr, Hackensack, New Jersey, United States|Montefiore Medical Center, Bronx, New York, United States|Clinical Research Alliance Inc., New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|Wake Forest University Health Sciences, Section on Hematology and Oncology, Winston-Salem, North Carolina, United States|Gabrail Cancer Center, Canton, Ohio, United States|The Christ Hospital, Cincinnati, Ohio, United States|Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, United States|Hematology/Oncology Associates of SC, Greenville, South Carolina, United States|Vanderbilt Ingram Cancer Center, Nashville, Tennessee, United States|MD Anderson, Houston, Texas, United States|The Methodist Cancer Center, Houston, Texas, United States|Scott & White Memorial Hospital, Temple, Texas, United States|University of Utah School of Medicine, Salt Lake City, Utah, United States|Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia|St. Vincent's Public Hospital Sydney, Darlinghurst, New South Wales, Australia|Saint George Hospital, Kogarah, New South Wales, Australia|Liverpool Hospital, Liverpool, New South Wales, Australia|Royal North Shore Hospital, Saint Leonards, New South Wales, Australia|Calvary Mater Newcastle, Waratah, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Royal Brisbane and Women's Hospital, Herston, Queensland, Australia|Haematology & Oncology Clinics of Australia, South Brisbane, Queensland, Australia|Haematology and Oncology Clinics of Australia at Chermside, South Brisbane, Queensland, Australia|Haematology and Oncology Clinics of Australia at Wesley, South Brisbane, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|The Queen Elizabeth Hospital, Woodville, South Australia, Australia|Box Hill Hospital, Box Hill, Victoria, Australia|Monash Medical Centre, Clayton, Victoria, Australia|Saint Vincent's Hospital, East Melbourne, Victoria, Australia|Western Hospital, Footscray, Victoria, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Sunshine Hospital, St. Albans, Victoria, Australia|Fremantle Hospital, Fremantle, Western Australia, Australia|Royal Perth Hospital, Perth, Western Australia, Australia|Medizinische Universität Innsbruck, Innsbruck, Tyrol, Austria|Krankenhaus der Elisabethinen Linz, I Interne Abteilung, Linz, Upper Austria, Austria|Wilhelminenspital der Stadt Wien, Wien, Vienna, Austria|Universitair Ziekenhuis Leuven, Leuven, Flemish Brabant, Belgium|Cliniques Universitaires UCL de Mont-Godinne, Yvoir, Namur, Belgium|Universitair Ziekenhuis Gent, Ghent, Oost-vlaanderen, Belgium|Ziekenhuis Netwerk Antwerpen, Antwerp, Belgium|Cliniques Universitaires Saint Luc, Brussels, Belgium|Universitair Ziekenhuis Brussel, Brussels, Belgium|Liga Norte Riograndense Contra o Câncer, Natal, RIO Grande DO Norte, Brazil|Clínica de Oncologia de Porto Alegre, Porto Alegre, RIO Grande DO SUL, Brazil|Hospital de Clínicas de Porto Alegre, Porto Alegre, RIO Grande DO SUL, Brazil|Hospital São Lucas da PUCRS, Porto Alegre, RIO Grande DO SUL, Brazil|Hemocentro Campinas-Unicamp, Campinas, SAO Paulo, Brazil|Hospital Universitário Clementino Fraga Filho da Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil|Instituto Centros Oncológicos Integrados de Educação e Pesquisa, Rio de Janeiro, Brazil|Instituto Nacional do Câncer-INCA, Rio de Janeiro, Brazil|Irmandade da Santa Casa de Misericórdia de São Paulo, São Paulo, Brazil|Military Medical Academy Hospital for Active Treatment, Sofia, Sofiya, Bulgaria|Shato, Ead, Sofia, Sofiya, Bulgaria|University Multiprofile Hospital for Active Treatment ""Sveti Georgi"" EAD, Plovdiv, Bulgaria|Multiprofile Hospital for Active Treatment, ""Sveta Marina'', Varna, Bulgaria|University of Alberta Hospital, Edmonton, Alberta, Canada|British Columbia Cancer Agency, Kelowna, British Columbia, Canada|Saint John Regional Hospital, Saint John, New Brunswick, Canada|Queen Elizabeth II Health Science Centre, Halifax, Nova Scotia, Canada|London Health Sciences Centre, London, Ontario, Canada|The Ottawa Hospital Regional Cancer Centre, Ottawa, Ontario, Canada|Windsor Regional Hospital, Windsor, Ontario, Canada|Hopital Maisonneuve-Rosemont, Montréal, Quebec, Canada|Fakultní nemocnice Královské Vinohrady, Praha 10, Praha, Czechia|Fakultní nemocnice Olomouc, Olomouc, Severomoravsky KRAJ, Czechia|FN Ostrava, Ostrava, Severomoravsky KRAJ, Czechia|Fakultní nemocnice Hradec Králové, Hradec Kralové, Vychodocesky KRAJ, Czechia|Fakultní nemocnice Brno, Brno, Czechia|Všeobecná fakultní nemocnice v Praze, Praha, Czechia|Centre Hospitalier de la Cote Basque, Bayonne, Aquitaine, France|Centre Hospitalier Universitaire Brest, Brest Cedex, Bretagne, France|Centre Hospitalier Universitaire de Rennes, Hôpital Pontchaillou, Rennes Cedex 9, Bretagne, France|Hopital Hotel-Dieu - Service d'Hematologie, Nantes, Cedex 1, France|Centre Henri-Becquerel, Rouen Cedex 1, Haute-normandie, France|Centre Hospitalier de Versailles, Le Chesnay, Ile-de-france, France|Hôpital Saint Louis, Paris, Ile-de-france, France|Hôpital Saint-Antoine, Paris, Ile-de-france, France|Hôpital Claude Huriez, Lille Cedex, NORD Pas-de-calais, France|Hôpital Hôtel-Dieu, Nantes cedex 1, PAYS DE LA Loire, France|Institut Paoli Calmettes, Marseille Cedex 9, Provence Alpes COTE D'azur, France|Centre Hospitalier Lyon Sud, Pierre Bénite Cedex, Rhone-alpes, France|Universitätsklinik Heidelberg, Heidelberg, Baden-wuerttemberg, Germany|Universitätsklinikum Tübingen, Tübingen, Baden-wuerttemberg, Germany|Universitätsklinikum Ulm, Ulm, Baden-wuerttemberg, Germany|Medizinische Klinik der Universität Würzburg, Würzburg, Bayern, Germany|Medizinische Hochschule Hannover, Hannover, Niedersachsen, Germany|Universitätsklinikum Aachen, Aachen, Nordrhein-westfalen, Germany|Universitätsklinikum Münster, Münster, Nordrhein-westfalen, Germany|Universitätsmedizin der Johannes Gutenberg Universität, Mainz, Rheinland-pfalz, Germany|Universitätsklinikum des Saarlandes, Homburg / Saar, Saarland, Germany|Klinikum Chemnitz gGmbH, Chemnitz, Sachsen, Germany|Universitätsklinikum Carl Gustav Carus, Med. Klinik und Poliklinik I, Dresden, Sachsen, Germany|Universitätsklinikum Leipzig, Leipzig, Sachsen, Germany|Universitätsklinikum Jena, Jena, Thuringen, Germany|Universitatsklinikum Freiburg, Freiburg, Germany|Universitätsklinikum Hamburg Eppendorf, Hamburg, Germany|Alexandra General Hospital, Athens, Attica, Greece|Bács-Kiskun Megyei Kórház Szegedi Tudományegyetem Általános Orvostudományi Kar Oktató Kórháza, Kecskemét, Bacs-kiskun, Hungary|Pécsi Tudományegyetem, Pécs, Baranya, Hungary|Szegedi Tudományegyetem, Szeged, Csongrad, Hungary|Debreceni Egyetem Klinikai Központ, Debrecen, Hajdu-bihar, Hungary|Egyesített Szent István és Szent László Kórház-Rendelointézet, Budapest, Hungary|Somogy Megyei Kaposi Mac okato Korhoz, Kaposvár, Hungary|Somogy Megyei Kaposi Mór Oktató Kórház, Kaposvár, Hungary|Rambam Health Corp., Haifa, Israel|Hadassah Medical Center, Jerusalem, Israel|Meir Medical Center, Kfar Saba, Israel|Tel Aviv Sourasky Medical Center, Tel Aviv, Israel|The Chaim Sheba Medical Center at Tel Hashomer, Tel Hashomer, Israel|IRCCS Centro di Riferimento Oncologico di Basilicata di Rionero in Vulture, Rionero in Vulture, Potenza, Italy|Azienda Ospedaliero-Univesitaria San Luigi Gonzaga, Orbassano, Torino, Italy|Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona, Ancona, Italy|Azienda Ospedaliero-Universitaria di Bologna - Policlinico S.Orsola-Malpighi, Bologna, Italy|Azienda Ospedaliera Spedali Civili di Brescia, Brescia, Italy|IRCCS Azienda Ospedaliera Universitaria San Martino, Genova, Italy|Azienda Ospedaliera Universitaria Maggiore della Carità, Novara, Italy|Azienda Unità Sanitaria Locale di Piacenza-Ospedale Guglielmo da Saliceto, Piacenza, Italy|Azienda Ospedaliera Pisana Ospedale Santa Chiara, Pisa, Italy|Aienda Policknico Umberto I di Roma, Roma, Italy|Azienda Policknico Umberto l di Roma, Roma, Italy|Università Tor Vergata Ospedale Sant Eugenio, Roma, Italy|Azienda Ospedaliera Universitaria Senese - Policlinico S. Maria alle Scotte, Siena, Italy|Azienda Ospedaliera Città della Salute e della Scienza di Torino, Torino, Italy|Nagoya City University Hospital, Nagoya City, Aichi, Japan|Toyohashi Municipal Hospital, Toyohashi, Aichi, Japan|National Hospital Organization Kyushu Cancer Center, Fukuoka-city, Fukuoka, Japan|Ogaki Municipal Hospital, Ogaki City, Gifu, Japan|Gunma University Hospital, Maebashi, Gunma, Japan|National Hospital Organization Nishigunma National Hospital, Shibukawa, Gunma, Japan|Sapporo Medical University Hospital, Sapporo, Hokkaido, Japan|Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan|Tokai University Hospital, Isehara, Kanagawa, Japan|Niigata Cancer Center Hospital, Niigata-city, Niigata, Japan|Osaka University Hospital, Suita, Osaka, Japan|Saitama Medical Center, Kawagoe, Saitama, Japan|Tochigi Cancer Center, Utsunomiya, Tochigi, Japan|National Cancer Center Hospital, Chuo-ku, Tokyo, Japan|The Cancer Institute Hospital Of Japanese Foundation For Cancer Research, Koto-ku, Tokyo, Japan|Toranornon Hospital, Shinagawa, Tokyo, Japan|Tokyo Medical University Hospital, Shinjuku, Tokyo, Japan|National Hospital Organization Disaster Medical Center, Tachikawa, Tokyo, Japan|Kyushu University Hospital, Fukuoka, Japan|Social Insurance Kyoto Hospital of All Japan Federation of Social Insurance Associations, Kyoto, Japan|University Hospital, Kyoto Prefectural University of Medicine, Kyoto, Japan|National Hospital Organization Okayama Medical Center, Okayama, Japan|Tokushima Prefectural Central Hospital, Tokushima, Japan|Japanese Red Cross Medical Center, Tokyo, Japan|Gachon University Gil Medical Center, Incheon, Gyeonggi-Do, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of|Pusan National University Hospital, Busan, Gyeongsangnam-Do, Korea, Republic of|Kyungpook National University Hospital, Daegu, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Seoul Saint Mary's Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|North Shore Hospital, North Shore City, Auckland, New Zealand|Middlemore Hospital, Otahuhu, Auckland, New Zealand|Auckland City Hospital, Grafton, Aukland, New Zealand|Christchurch Hospital, Christchurch, New Zealand|Dunedin Hospital, Dunedin, New Zealand|Specjalistyczny Szpital Miejski im. Mikolaja Kopernika, Torun, Kujawsko-Pomorskie, Poland|Zamojski Szpital Niepubliczny Sp. z o.o., Zamosc, Lubelskie, Poland|Szpital Uniwersytecki w Krakowie, Krakow, Malopolskie, Poland|Instytut Hematologii i Transfuzjologii, Warszawa, Mazowieckie, Poland|Uniwersyteckie Centrum Kliniczne, Gdansk, Pomorskie, Poland|Samodzielny Publiczny Zaklad Opieki Zdrowotnej Zespól Szpitali Miejskich, Chorzów, Slaskie, Poland|Szpital Kliniczny Przemienienia Panskiego Uniwersytetu Medycznego im K. Marcinkowskiego w Poznaniu, Poznan, Wielkopolskie, Poland|Spitalul Universitar de Urgenta Bucuresti, Bucharest, Bucuresti, Romania|Policlinica de Diagnostic Rapid SA, Compartiment Medical Oncologie-Hematologie, Brasov, Romania|Spitalul Clinic Judetean de Urgenta Brasov (Bumbea, Horia), Brasov, Romania|Institutul Clinic Fundeni, Bucuresti, Romania|Institutul Regional de Oncologie Iasi, Iasi, Romania|Republican Clinical Hospital #1, Izhevsk, Russian Federation|City Clinical Hospital n.a. S. P. Botkin, Moscow, Russian Federation|Non-state Healthcare Institution ""N.A. Semashko Central Clinical Hospital #2 of JSC ""Russian Railway, Moscow, Russian Federation|Ryazan Regional Clinical Hospital, Ryazan, Russian Federation|Clinical Hospital Number 31, Saint Petersburg, Russian Federation|Federal Almazov Medical Research Centre, Saint Petersburg, Russian Federation|FGU Russian Scientific Research Institute of Hematology and Transfusiology, Saint Petersburg, Russian Federation|First Saint Petersburg I.P. Pavlov State Medical University, Saint Petersburg, Russian Federation|GUZ Samara Regional Clinical Hospital n.a. M.I. Kalinin, Samara, Russian Federation|National University Cancer Institute, Singapore, Singapore|Singapore General Hospital, Singapore, Singapore|Singapore Oncology Consultants, Singapore, Singapore|Univerzitná nemocnica Bratislava, Bratislava, Slovakia|Hospital Son Llàtzer, Palma de Mallorca, Baleares, Spain|Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain|Hospital Clinic I Provincial de Barcelona, Barcelona, Spain|Institut Universitari Dexeus, Barcelona, Spain|Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-San Chinarro, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario La Princesa, Madrid, Spain|Hospital Clínico Universitario de Salamanca, Salamanca, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Hospital Universitari i Politecnic La Fé de Valencia, Valencia, Spain|Chang Gung Memorial Hospital, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan|National Cheng-Kung University Hospital, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Chang Gung Medical Foundation-LinKou Branch, Tao-Yuan, Taiwan|King Chulalongkorn Memorial Hospital, Bangkok, Bangkok Metropolis, Thailand|Ramathibodi Hospital, Bangkok, Bangkok Metropolis, Thailand|Srinagarind Hospital, Khon Kaen, Thailand|City Hematology Center, Dnepropetrovsk, Dnipropretrovsk, Ukraine|Municipal Institution of Health Protection ""Clinical Hospital #8"", Kharkov, Kharkiv, Ukraine|Cherkassy Regional Oncology Center, Cherkassy, Ukraine|MI ""Dnipropetrovsk City Multifield Clinical Hospital #4"" of Dnipropetrovsk Regional Council"", City Hematology Center, Dnipropetrovsk, Ukraine|Institute of Urgent and Reparative Surgury of Ukraine Academy of Medical Sciences, Donetsk, Ukraine|Khmelnytsky Regional Clinical Hospital, Khmelnytsky, Ukraine|Khmelnytsky Regional Hospital, Department of Hematology, Khmelnytsky, Ukraine|National Institute of Cancer, Oncohematology Department, Kiev, Ukraine|Kyiv Bone Marrow Transplantation Center, Kyiv, Ukraine|Lviv Regional Oncology Dispensary, Lviv, Ukraine|Lviv State Oncology Regional Treatment-Prophylactic Center, Department of Chemotherapy, Lviv, Ukraine|Regional Clinical Hospital, Mykolayiv, Ukraine|Royal Free Hospital, London, England, United Kingdom|University College Hospital, London, England, United Kingdom|Manchester Royal Infirmary, Manchester, England, United Kingdom|Nottingham University Hospitals NHS Trust, Nottingham, England, United Kingdom|Churchill Hospital, Oxford, England, United Kingdom|Derriford Hospital, Plymouth, England, United Kingdom|Royal Hallamshire Hospital, Sheffield, England, United Kingdom|Royal Marsden Hospital, Surrey, England, United Kingdom|Royal Wolverhampton Hospitals Trust, Wolverhampton, England, United Kingdom",
